Cargando…
Gut microbiome and pancreatic cancer cachexia: An evolving relationship
Nearly 80% of patients with pancreatic ductal adenocarcinoma (PDAC) develop cachexia along their disease course. Cachexia is characterized by progressive weight loss, muscle wasting, and systemic inflammation and has been linked to poorer outcomes and impairments in quality of life. Management of PD...
Autores principales: | Hendifar, Andrew, Akinsola, Rasaq, Muranaka, Hayato, Osipov, Arsen, Thomassian, Shant, Moshayedi, Natalie, Yang, Julianne, Jacobs, Jonathan, Devkota, Suzanne, Bhowmick, Neil, Gong, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305570/ https://www.ncbi.nlm.nih.gov/pubmed/36051103 http://dx.doi.org/10.4251/wjgo.v14.i7.1218 |
Ejemplares similares
-
Advances in Pancreatic Ductal Adenocarcinoma Treatment
por: Anderson, Eric M., et al.
Publicado: (2021) -
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022) -
Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022) -
Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
por: Gong, Jun, et al.
Publicado: (2023) -
Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
por: Gubatan, John, et al.
Publicado: (2021)